Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 13(1): 19240, 2023 11 07.
Artigo em Inglês | MEDLINE | ID: mdl-37935733

RESUMO

Hepatitis E virus (HEV) genotype 3 infections in Germany are mainly transmitted zoonotically through the consumption of swine meat. Furthermore, there is evidence that pets might come into contact with HEV, but the relevance of companion animals as possible sources of HEV transmission in Germany still needs to be defined. A monitoring study was therefore carried out on dogs, cats, and horses from Germany. In total 365 serum samples from pets (124 dogs, 119 cats, and 122 horses) were tested for HEV by PCR and for anti-HEV antibodies by a commercial ELISA. The HEV seroprevalence determined by the sero-assay varied significantly between dogs (10%), cats (6%), and horses (2%). Liver injury-related enzymes, alanine transaminase (ALT), and aspartate transaminase (AST) showed no differences between HEV-positive or negative animals. None of the pet serum samples tested positive for PCR. This serological study suggests that dogs and cats are significantly exposed to HEV in Germany, while horses are of minor relevance.


Assuntos
Doenças do Gato , Doenças do Cão , Vírus da Hepatite E , Hepatite E , Animais , Gatos , Cães , Doenças do Cão/epidemiologia , Hepatite E/epidemiologia , Hepatite E/veterinária , Cavalos , Estudos Soroepidemiológicos , Viremia
4.
United European Gastroenterol J ; 6(1): 104-111, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29435320

RESUMO

BACKGROUND: Since introduction of the MELD score in the liver allograft allocation system, renal insufficiency has emerged as an increasing problem. Here we evaluated the course of kidney function in patients with advanced renal insufficiency prior to liver transplantation (LT). METHODS: A total of 254 patients undergoing LT at the University Medical Centre Hamburg-Eppendorf (2011-2015) were screened for renal impairment (GFR < 30 ml/min) prior to LT in this observational study. RESULTS: Eighty (32%) patients (median 60 years; M/F: 48/32) had significant renal impairment prior to LT. Median follow-up post-LT was 619 days. Patient survival at 90 days, one year and two years was 76%, 66% and 64%, respectively. Need for dialysis postoperatively but not preoperatively was associated with increased mortality (p < 0.05). Renal function improved in 75% of survivors, but 78% of patients had chronic kidney disease ≥ stage 3 at end of follow-up. Of eight (16%) survivors remaining on long-term dialysis, so far only four patients have received a kidney transplant. CONCLUSION: Postoperative dialysis affected long-term mortality. In 75% of survivors renal function improved, but still the majority of patients had an impaired renal function (CKD stage 3-5) at end of follow-up. Future studies should elucidate the impact of kidney dysfunction and dialysis on recipients' long-term survival.

5.
Med Klin Intensivmed Notfmed ; 113(3): 174-183, 2018 04.
Artigo em Alemão | MEDLINE | ID: mdl-27241777

RESUMO

Acute liver failure (ALF) is a rare condition with fatal outcome. Characteristic is rapid onset of liver damage without preexisting liver diseases, including hepatic encephalopathy and coagulopathy. Early and correct diagnosis is essential for further management of patients, since diagnosis impacts therapy choice. Survival of patients with ALF has improved dramatically due to advances in critical care medicine and the use of liver transplantation.


Assuntos
Encefalopatia Hepática , Falência Hepática Aguda , Transplante de Fígado , Cuidados Críticos , Humanos , Falência Hepática Aguda/diagnóstico , Falência Hepática Aguda/terapia
6.
Med Klin Intensivmed Notfmed ; 111(5): 447-52, 2016 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-26070920

RESUMO

Interactions between the hepatic portal and cardiovascular systems are frequently found in patients with liver disease. Cirrhotic cardiomyopathy (CCMP) is defined as reduced cardiac function in patients with liver cirrhosis in the absence of other known causes of cardiac disease. The typical hyperdynamic circulatory state by means of increased cardiac output and reduced systemic vascular resistance may mask left ventricular failure. Portopulmonary hypertension (POPH) is defined as increased pulmonary arterial pressure and the presence of portal hypertension, and is associated with increased mortality. Targeted medical therapies include vasodilators such as prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Hypoxic or ischaemic hepatitis (HH) is defined by a sharp increase of serum aminotransferase levels due to liver cell necrosis as result of cardiac, circulatory or respiratory failure. An overview of these diseases is provided in this article.


Assuntos
Cardiomiopatias/complicações , Cardiomiopatias/fisiopatologia , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Débito Cardíaco/fisiologia , Cardiomiopatias/diagnóstico , Cardiomiopatias/terapia , Terapia Combinada , Diagnóstico Diferencial , Humanos , Hipertensão Portal/complicações , Hipertensão Portal/diagnóstico , Hipertensão Portal/fisiopatologia , Hipertensão Portal/terapia , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/fisiopatologia , Hipertensão Pulmonar/terapia , Unidades de Terapia Intensiva , Cirrose Hepática/diagnóstico , Cirrose Hepática/terapia , Prognóstico , Resistência Vascular/fisiologia , Disfunção Ventricular Esquerda/complicações , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/fisiopatologia , Disfunção Ventricular Esquerda/terapia
7.
Med Klin Intensivmed Notfmed ; 109(4): 228-34, 2014 May.
Artigo em Alemão | MEDLINE | ID: mdl-24770888

RESUMO

Liver dysfunction is frequently observed in critically ill patients. Its occurrence is associated with high morbidity and mortality. The most frequent entities of hepatic dysfunction in the intensive care unit are shock liver and cholestatic liver dysfunction with incidence rates up to 10 and 30 %, respectively.Both conditions are frequently triggered by hypoxic and/or ischemic events, most commonly cardiogenic shock and sepsis/septic shock. However, several other potential contributors have been identified especially for cholestatic liver dysfunction. Apart from chronic liver diseases and malignancies, iatrogenic factors such as total parenteral nutrition, high pressure ventilation, surgical procedures, drugs and blood transfusions promote its occurrence.In shock liver and in cholestatic liver disease, early detection and therapy of the underlying disease is the only established treatment.


Assuntos
Colestase/fisiopatologia , Colestase/terapia , Cuidados Críticos/métodos , Falência Hepática/fisiopatologia , Falência Hepática/terapia , Insuficiência de Múltiplos Órgãos/fisiopatologia , Insuficiência de Múltiplos Órgãos/terapia , Diagnóstico Precoce , Humanos , Fígado/fisiopatologia , Falência Hepática/etiologia , Insuficiência de Múltiplos Órgãos/etiologia , Prognóstico
8.
Med Klin Intensivmed Notfmed ; 109(4): 246-51, 2014 May.
Artigo em Alemão | MEDLINE | ID: mdl-24770889

RESUMO

Acute and acute-on-chronic liver failure are often associated with development of organ failure. Its occurrence is associated with high morbidity and mortality. Extracorporeal replacement therapies are frequently necessary in these patient populations. Replacement therapies can be divided into renal replacement therapies and liver support therapies. These therapies consist of artificial liver support systems (i.e., MARS(®) system, Prometheus(®)), which are able to remove water-soluble and albumin-bound toxins, and of bioartifical liver support systems. This manuscript provides a review of current practice in the extracorporeal support of patients with liver diseases in the intensive care unit.


Assuntos
Cuidados Críticos/métodos , Unidades de Terapia Intensiva , Falência Hepática/terapia , Fígado Artificial , Insuficiência de Múltiplos Órgãos/terapia , Terapia de Substituição Renal , Humanos , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Cirrose Hepática/terapia , Falência Hepática/diagnóstico , Falência Hepática/etiologia , Insuficiência de Múltiplos Órgãos/diagnóstico , Insuficiência de Múltiplos Órgãos/etiologia
9.
Med Klin Intensivmed Notfmed ; 109(4): 235-9, 2014 May.
Artigo em Alemão | MEDLINE | ID: mdl-24763525

RESUMO

Pulmonary-hepatic vascular disorders are frequent complications in patients with portal hypertension and cirrhosis. Hepatopulmonary syndrome (HPS), portopulmonary hypertension (POPH), and hepatic hydrothorax are relevant disease entities in these patients. HPS occurs in up to 30 % of patients with cirrhosis and is associated with a more than 2-fold increased mortality. The diagnosis of HPS should be established early by arterial blood gas analysis and contrast-enhanced echocardiography, whereas POPH is diagnosed by the presence of pulmonary arterial hypertension evaluated via right heart catheterization and the presence of portal hypertension. Therapeutic options include initiation of long-term oxygen therapy and liver transplantation in patients with severe HPS. Patients with POPH should receive targeted medical therapies with endothelin receptor antagonists, phosphodiesterase-5 inhibitors and/or prostanoids. In contrast, ß-blockers should be avoided. This review summarizes current knowledge regarding pulmonary-hepatic vascular disorders, with a focus on HPS.


Assuntos
Cuidados Críticos/métodos , Síndrome Hepatopulmonar/terapia , Falência Hepática/terapia , Insuficiência de Múltiplos Órgãos/terapia , Terapia Combinada , Síndrome Hepatopulmonar/diagnóstico , Síndrome Hepatopulmonar/fisiopatologia , Humanos , Fígado/fisiopatologia , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Cirrose Hepática/terapia , Falência Hepática/diagnóstico , Falência Hepática/fisiopatologia , Pulmão/fisiopatologia , Insuficiência de Múltiplos Órgãos/diagnóstico , Insuficiência de Múltiplos Órgãos/fisiopatologia
10.
Eur J Clin Nutr ; 68(6): 707-11, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24424078

RESUMO

BACKGROUND/OBJECTIVES: Women and men differ in substrate and energy metabolism. Such differences may affect energy requirements during the acute phase of critical illness. SUBJECTS/METHODS: Data of 155 critically ill medical patients were reviewed for this study. Indirect calorimetry in each patient was performed within the first 72 h following admission to the medical intensive care unit after an overnight fast. RESULTS: In overweight (body mass index (BMI) ≥25 kg/m(2)) but not in normal-weight patients, resting energy expenditure (REE) adjusted for body weight (REEaBW) differed significantly between women and men (17.2 (interquartile range (IQR) 15.2-20.7) vs 20.9 (IQR 17.9-23.4) kcal/kg/day, P<0.01). Similarly, REE adjusted for ideal body weight (REEaIBW) was significantly lower in women compared with men (25.5 (IQR 22.6-28.1) vs 28.0 (IQR 25.2-30.0) kcal/kg/day, P<0.05). In overweight patients, gender was identified as an independent predictor of REEaBW in the multivariate regression model (r=-2.57 (95% CI -4.57 to -0.57); P<0.05), even after adjustment for age, simplified acute physiology score (SAPS II), body temperature, body weight and height. CONCLUSIONS: REEaBW decreases with increasing body mass in both sexes. This relationship differs between women and men. Overweight critically ill women show significantly lower REEaBW and REEaIBW, respectively, compared with men. These findings could affect the current practice of nutritional support during the early phase of critical illness.


Assuntos
Estado Terminal , Metabolismo Energético , Obesidade/metabolismo , Fatores Sexuais , Adulto , Idoso , Calorimetria Indireta , Feminino , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA